Copula-Based Model for Incorporating Single-Agent Historical Data into Dual-Agent Phase I Cancer Trials

References

• Bedard, P. L., Tabernero, J., Janku, F., Wainberg, Z. A., Paz-Ares, L., Vansteenkiste, J., Cutsem, E. V., Pérez-García, J., Stathis, A., Britten, C. D., Le, N., Carter, K., Demanse, D., Csonka, D., Peters, M., Zubel, A., Nauwelaerts, H., and Sessa, C. (2014), “A Phase Ib Dose-Escalation Study of the Oral pan-PI3K Inhibitor buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors,” Clinical Cancer Research, 21, 730–738. DOI: 10.1158/1078-0432.CCR-14-1814.
   PubMed Web of Science ®Google Scholar
• Bendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., Buck, S. S. D., Ru, Q. C., Peters, M., Goldbrunner, M., and Baselga, J. (2012), “Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors,” Journal of Clinical Oncology, 30, 282–290. DOI: 10.1200/JCO.2011.36.1360.
   PubMed Web of Science ®Google Scholar
• Chen, M.-H., and Ibrahim, J. G. (2006), “The Relationship between the Power Prior and Hierarchical Models,” Bayesian Analysis, 1, 551–574. DOI: 10.1214/06-BA118.
   Web of Science ®Google Scholar
• Cheung, Y. (2011), Dose Finding by the Continual Reassessment Method, Boca Raton: CRC Press/Taylor & Francis Group.
   Google Scholar
• Daud, A. I., Krishnamurthi, S. S., Saleh, M. N., Gitlitz, B. J., Borad, M. J., Gold, P. J., Chiorean, E. G., Springett, G. M., Abbas, R., Agarwal, S., Bardy-Bouxin, N., Hsyu, P.-H., Leip, E., Turnbull, K., Zacharchuk, C., and Messersmith, W. A. (2011), “Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors,” Clinical Cancer Research, 18, 1092–1100. DOI: 10.1158/1078-0432.CCR-11-2378.
   PubMed Web of Science ®Google Scholar
• Duan, Y., Ye, K., and Smith, E. P. (2006), “Evaluating Water Quality using Power Priors to Incorporate Historical Information,” Environmetrics, 17, 95–106. DOI: 10.1002/env.752.
   Web of Science ®Google Scholar
• Felip, E., de Braud, F. G., Maur, M., Loong, H. H., Shaw, A. T., Vansteenkiste, J. F., John, T., Liu, G., Lolkema, M. P., Selvaggi, G., Giannone, V., Cazorla, P., Baum, J., Balbin, O. A., Wang, L. V., Lau, Y. Y., Scott, J. W., and Tan, D. S.-W. (2020), “Ceritinib Plus Nivolumab in Patients with Advanced ALK-Rearranged non–small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1b Study,” Journal of Thoracic Oncology, 15, 392–403. DOI: 10.1016/j.jtho.2019.10.006.
   PubMed Web of Science ®Google Scholar
• Gasparini, M. (2013), “General Classes of Multiple Binary Regression Models in Dose Finding Problems for Combination Therapies,” Journal of the Royal Statistical Society, Series C, 62, 115–133. DOI: 10.1111/j.1467-9876.2012.01054.x.
   Web of Science ®Google Scholar
• Gravestock, I., Held, L., and consortium, C.-N. (2017), “Adaptive Power Priors with Empirical Bayes for Clinical Trials,” Pharmaceutical Statistics, 16, 349–360. DOI: 10.1002/pst.1814.
   PubMed Web of Science ®Google Scholar
• Hashizume, K., Tshuchida, J., and Sozu, T. (2021), “Flexible Use of Copula-Type Model for Dose-Finding in Drug Combination Clinical Trials,” Biometrics, 78, 1651–1661. DOI: 10.1111/biom.13510.
   PubMed Web of Science ®Google Scholar
• Hobbs, B. P., Carlin, B. P., Mandrekar, S. J., and Sargent, D. J. (2011), “Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials,” Biometrics, 67, 1047–1056. DOI: 10.1111/j.1541-0420.2011.01564.x.
   PubMed Web of Science ®Google Scholar
• Ibrahim, J. G., Chen, M.-H., and Sinha, D. (2003), “On Optimality Properties of the Power Prior,” Journal of the American Statistical Association, 98, 204–213. DOI: 10.1198/016214503388619229.
   Web of Science ®Google Scholar
• Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., Peddareddigari, V. G., Le, N. T., Hart, L., Bendell, J. C., Eckhardt, G., Kurzrock, R., Flaherty, K., Burris, H. A., and Messersmith, W. A. (2012), “Safety, Pharmacokinetic, Pharmacodynamic, and Efficacy Data for the Oral MEK Inhibitor Trametinib: A Phase 1 Dose-Escalation Trial,” The Lancet Oncology, 13, 773–781. DOI: 10.1016/S1470-2045(12)70270-X.
   PubMed Web of Science ®Google Scholar
• Isakoff, S. J., Wang, D., Campone, M., Calles, A., Leip, E., Turnbull, K., Bardy-Bouxin, N., Duvillié, L., and Calvo, E. (2014), “Bosutinib plus Capecitabine for Selected Advanced Solid Tumours: Results of a Phase 1 Dose-Escalation Study,” British Journal of Cancer, 11, 2058–2066. DOI: 10.1038/bjc.2014.508.
   Google Scholar
• Legedza, A. T. R., and Ibrahim, J. G. (2001), “Heterogeneity in Phase I Clinical Trials: Prior Elicitation and Computation Using the Continual Reassessment Method,” Statistics in Medicine, 20, 867–882. DOI: 10.1002/sim.701.
   PubMed Web of Science ®Google Scholar
• Lin, R., and Yin, G. (2017), “Bayesian Optimal Interval Design for Dose Finding in Drug-Combination Trials,” Statistical Methods in Medical Research, 26, 2155–2167. DOI: 10.1177/0962280215594494.
   PubMed Web of Science ®Google Scholar
• Liu, S., and Yuan, Y. (2015), “Bayesian Optimal Interval Designs for Phase I Clinical Trials,” Journal of the Royal Statistical Society, Series C, 64, 507–523. DOI: 10.1111/rssc.12089.
   Web of Science ®Google Scholar
• Manji, A., Brana, I., Amir, E., Tomlinson, G., Tannock, I. F., Bedard, P. L., Oza, A., Siu, L. L., and Razak, A. R. A. (2013), “Evolution of Clinical Trial Design in Early Drug Development: Systematic Review of Expansion Cohort Use in Single-Agent Phase I Cancer Trials,” Journal of Clinical Oncology, 31, 4260–4267. DOI: 10.1200/JCO.2012.47.4957.
   PubMed Web of Science ®Google Scholar
• Neuenschwander, B., Capkun-Niggli, G., Branson, M., and Spiegelhalter, D. J. (2010), “Summarizing Historical Information on Controls in Clinical Trials,” Clinical Trials, 7, 5–18. DOI: 10.1177/1740774509356002.
   PubMed Web of Science ®Google Scholar
• Neuenschwander, B., Roychoudhury, S., and Schmidli, H. (2016), “On the Use of Co-data in Clinical Trials,” Statistics in Biopharmaceutical Research, 8, 345–354. DOI: 10.1080/19466315.2016.1174149.
   Web of Science ®Google Scholar
• Nikolakopoulos, S., van der Tweel, I., and Roes, K. C. B. (2018), “Dynamic Borrowing through Empirical Power Priors that Control Type I Error,” Biometrics, 74, 874–880. DOI: 10.1111/biom.12835.
   PubMed Web of Science ®Google Scholar
• Ollier, A., Morita, S., Ursino, M., and Zohar, S. (2020), “An Adaptive Power Prior for Sequential Clinical Trials – Application to Bridging Studies,” Statistical Methods in Medical Research, 29, 2282–2294. DOI: 10.1177/0962280219886609.
   PubMed Web of Science ®Google Scholar
• Pan, H., Lin, R., Zhou, Y., and Yuan, Y. (2020), “Keyboard Design for Phase I Drug-Combination Trials,” Contemporary Clinical Trials, 92, 105972. DOI: 10.1016/j.cct.2020.105972.
   PubMed Web of Science ®Google Scholar
• Riviere, M.-K., Yuan, Y., Dubois, F., and Zohar, S. (2014), “A Bayesian Dose-Finding Design for Drug Combination Clinical Trials based on the Logistic Model,” Pharmaceutical Statistics, 13, 247–257. DOI: 10.1002/pst.1621.
   PubMed Web of Science ®Google Scholar
• Schmidli, H., Gsteiger, S., Roychoudhury, S., O’Hagan, A., Spiegelhalter, D., and Neuenschwander, B. (2014), “Robust Meta-Analytic-Predictive Priors in Clinical Trials with Historical Control Information,” Biometrics, 70, 1023–1032. DOI: 10.1111/biom.12242.
   PubMed Web of Science ®Google Scholar
• Thall, P. F., Millikan, R. E., Mueller, P., and Lee, S.-J. (2003), “Dose-Finding with Two Agents in Phase I Oncology Trials,” Biometrics, 59, 487–496. DOI: 10.1111/1541-0420.00058.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA) (2018), “Expansion Cohorts: Use in First-in-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics (Guidance for Industry),” https://www.fda.gov/media/115172/download. Accessed: 2021–01-06.
   Google Scholar
• Wang, K., and Ivanova, A. (2005), “Two-Dimensional Dose Finding in Discrete Dose Space,” Biometrics, 61, 217–222. DOI: 10.1111/j.0006-341X.2005.030540.x.
   PubMed Web of Science ®Google Scholar
• Yin, G., and Yuan, Y. (2009a), “Bayesian Dose Finding in Oncology for Drug Combinations by Copula Regression,” Journal of the Royal Statistical Society, Series C, 58, 211–224. DOI: 10.1111/j.1467-9876.2009.00649.x.
   Web of Science ®Google Scholar
• Yin, G., and Yuan, Y. (2009b), “Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials,” Journal of the American Statistical Association, 104, 954–968.
   Web of Science ®Google Scholar
• Yin, G., and Yuan, Y. (2009c), “A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents,” Biometrics, 65, 866–875.
   PubMed Web of Science ®Google Scholar